DMD Community Eyes First Cell Therapy Approval Following FDA’s Acceptance of Deramiocel Submission

With a scheduled PDUFA date of August 31, 2025, deramiocel looks to become the first marketed treatment for cardiomyopathy in DMD, one of the leading causes of death in this patient population.:

Source: Neurology Read More